Bocouture 50 E Norvège - norvégien - Statens legemiddelverk

bocouture 50 e

merz pharmaceuticals gmbh - botulinumtoksin type a - pulver til injeksjonsvæske, oppløsning - 50 e

Bocouture 100 E Norvège - norvégien - Statens legemiddelverk

bocouture 100 e

merz pharmaceuticals gmbh - botulinumtoksin type a - pulver til injeksjonsvæske, oppløsning - 100 e

Topotecan Eagle Union européenne - norvégien - EMA (European Medicines Agency)

topotecan eagle

eagle laboratories ltd.    - topotecan (as hydrochloride) - carcinoma; small cell lung carcinoma - antineoplastiske og immunmodulerende midler - topotecan-monoterapi er indisert for behandling av pasienter med tilbaketrukket småcellet lungekreft (sclc) for hvem gjenbehandling med førstelinjens regime ikke anses hensiktsmessig. topotecan i kombinasjon med cisplatin er indisert for pasienter med karsinom i cervix tilbakevendende etter strålebehandling, og for pasienter med stadium ivb sykdom. pasienter med tidligere eksponering for cisplatin krever en vedvarende behandling gratis intervall for å rettferdiggjøre behandling med kombinasjon.

Jynneos - Norvège - norvégien - Statens legemiddelverk

jynneos -

- - koppervirus ankara, levende, svekket - injeksjonsvæske, suspensjon - 0.025 mg

Zolsketil pegylated liposomal Union européenne - norvégien - EMA (European Medicines Agency)

zolsketil pegylated liposomal

accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doxorubicin - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.

Nexavar 200 mg Norvège - norvégien - Statens legemiddelverk

nexavar 200 mg

abacus medicine a/s - sorafenibtosylat - tablett, filmdrasjert - 200 mg

Ketoconazole HRA Union européenne - norvégien - EMA (European Medicines Agency)

ketoconazole hra

hra pharma rare diseases - ketoconazole - cushing syndrome - antimykotika for systemisk bruk - ketokonazol hra er indisert for behandling av endogent cushings syndrom hos voksne og ungdom over 12 år.

Renitec Comp Mite 20 mg / 6 mg Norvège - norvégien - Statens legemiddelverk

renitec comp mite 20 mg / 6 mg

merck sharp & dohme b.v. - enalaprilmaleat / hydroklortiazid - tablett - 20 mg / 6 mg

Renitec Comp Mite 20 mg / 6 mg Norvège - norvégien - Statens legemiddelverk

renitec comp mite 20 mg / 6 mg

orifarm as - enalaprilmaleat / hydroklortiazid - tablett - 20 mg / 6 mg

Zestoretic 20 mg / 12.5 mg Norvège - norvégien - Statens legemiddelverk

zestoretic 20 mg / 12.5 mg

atnahs pharma netherlands b.v. - lisinoprildihydrat / hydroklortiazid - tablett - 20 mg / 12.5 mg